Business
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C., January 08, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025.
About this update from Simulations Plus, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/5c414aa4f2b7244e5d3754e9abf61d83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vFIlJP0MxHqT6Au5TDcNuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5c414aa4f2b7244e5d3754e9abf61d83","width":480,"height":480}},"lazy":false},{"type":"text","content":"Investor Day on January 21, 2026, to present new product vision and AI solutions","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., January 08, 2026--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025.","length":359,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights (as compared to first quarter 2025)","length":75,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue decreased 3% to $18.4 million","length":43,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Software revenue decreased 17% to $8.9 million, representing 48% of total revenue","length":81,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Services revenue increased 16% to $9.5 million, representing 52% of total revenue","length":81,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit was $10.9 million and gross margin was 59%, compared to $10.2 million and 54%","length":90,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $0.7 million and diluted earnings per share of $0.03, compared to net income of $0.2 million and diluted EPS of $0.01","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $3.5 million, representing 19% of total revenue, compared to $4.5 million, representing 24% of total revenue","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted net income of $2.6 million and adjusted diluted EPS of $0.13 compared to adjusted net income of $3.4 millio...